As of June 21, 2025, Prothena Corporation PLC (PRTA) reports a ROA (Return on Assets) of -22.36%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Prothena Corporation PLC's ROA (Return on Assets)
Over recent years, Prothena Corporation PLC's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -22.36% |
| 2023-12-31 | -21.11% |
| 2022-12-31 | -15.42% |
| 2021-12-31 | 10.99% |
| 2020-12-31 | -33.36% |
This slight downward trend highlights how Prothena Corporation PLC manages its efficiency in using assets to generate earnings over time.
Comparing Prothena Corporation PLC's ROA (Return on Assets) to Peers
To better understand Prothena Corporation PLC's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Prothena Corporation PLC (PRTA) | -22.36% |
| Inhibrx Inc (INBX) | 932.36% |
| Alkermes Plc (ALKS) | 17.85% |
| Horizon Therapeutics PLC (HZNP) | 5.72% |
| Amarin Corporation PLC (AMRN) | -11.99% |
| ESSA Pharma Inc (EPIX) | -22.30% |
Compared to its competitors, Prothena Corporation PLC's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.